Motilal Oswal: Jubilant Life Sciences - Covid-19 Led Aberration For The Quarter
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Jubilant Life Sciences Ltd. Q1 FY21 performance was adversely impacted due to Covid-19-led slowdown in demand for its Radiopharma and Life Science Chemicals segment.
The temporary two month shutdown of its Nanjangud plant (used for the contract development and manufacturing organization (CDMO) business) worsened the situation.
We reduce our earnings estimate by 14%/2% for FY21/FY22 to factor the Covid-19-led impact on the business.
We remain positive on Jubilant Life Sciences on the back of:
1) strong demand recovery in Specialty Pharma, CDMO, and Specialty Intermediates,
2) new product additions, and 3) improved operating leverage.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.